Key facts
- CorriXR Therapeutics’s last known valuation is $25.0M (Jul 2022).
- It has raised $25.0M across 1 recorded rounds; the latest was Early Stage VC ($6.5M) in Jun 2022.
- Notable investors include National Institutes of Health, Cortado Ventures, State Small Business Credit Initiative, Brookhaven Bio, ChristianaCare — 6 tracked in total.
- CorriXR Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Jan 2024 ($6.5M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for CorriXR Therapeutics
Funding rounds
1 roundsAbout CorriXR Therapeutics
Operator of a gene editing company, intended to develop therapeutics and treat cancer using CRISPR technology, met with the FDA to discuss plans for a clinical trial. The company's platform technology uses Cas molecule to disable the genome of a tumor cell but not the genome of a healthy cell, conferring target selectivity, enabling healthcare professionals a broad-based combinatorial therapeutic regimen for the treatment of solid tumors.
- Sector
- Healthcare
- HQ
- Newark, DE, United States
- Founded
- 2022
- Employees
- 6
- Website
- corrixr.com/
- Ownership
- Privately Held (backing)
CorriXR Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CorriXR Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CorriXR Therapeutics in its N-PORT filings yet. We sweep new filings monthly.